• 1
    Markovic-Plese S, McFarland HF. Immunopathogenesis of the multiple sclerosis lesion. Curr Neurol Neurosci Rep 2001; 1:25762.
  • 2
    Zozulya AL, Wiendl H. The role of regulatory T cells in multiple sclerosis. Nat Clin Pract Neurol 2008; 4:38498.
  • 3
    McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 2007; 8:91319.
  • 4
    Liu GZ, Gomes AC, Fang LB, Gao XG, Hjelmstrom P. Decreased 4-1BB expression on CD4+CD25(high) regulatory T cells in peripheral blood of patients with multiple sclerosis. Clin Exp Immunol 2008; 154:229.
  • 5
    Haas J, Fritzsching B, Trubswetter P et al. Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis. J Immunol 2007; 179:132230.
  • 6
    Feger U, Luther C, Poeschel S, Melms A, Tolosa E, Wiendl H. Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients. Clin Exp Immunol 2007; 147:41218.
  • 7
    Venken K, Hellings N, Hensen K et al. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression. J Neurosci Res 2006; 83:143246.
  • 8
    Fritzsching B, Korporal M, Haas J, Krammer PH, Suri-Payer E, Wildemann B. Similar sensitivity of regulatory T cells towards CD95L-mediated apoptosis in patients with multiple sclerosis and healthy individuals. J Neurol Sci 2006; 251:917.
  • 9
    Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199:9719.
  • 10
    Haas J, Hug A, Viehover A et al. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol 2005; 35:334352.
  • 11
    Yamamura T, Takahashi K, Araki M. Multiple sclerosis and regulatory cells. Nippon Rinsho 2005; 63 (Suppl. 5):4226.
  • 12
    De Andres C, Aristimuno C, De Las Heras V et al. Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing–remitting multiple sclerosis. J Neuroimmunol 2007; 182:20411.
  • 13
    Frisullo G, Nociti V, Iorio R et al. Glucocorticoid treatment reduces T-bet and pSTAT1 expression in mononuclear cells from relapsing remitting multiple sclerosis patients. Clin Immunol 2007; 124:28493.
  • 14
    Whitaker JN, Layton BA, Herman PK, Kachelhofer RD, Burgard S, Bartolucci AA. Correlation of myelin basic protein-like material in cerebrospinal fluid of multiple sclerosis patients with their response to glucocorticoid treatment. Ann Neurol 1993; 33:1017.
  • 15
    Wiendl H, Kieseier BC, Gold R, Hohlfeld R, Bendszus M, Hartung HP. Revision of McDonald's new diagnostic criteria for multiple sclerosis. Nervenarzt 2006; 77:745.
  • 16
    Berhanu A, Huang J, Watkins SC, Okada H, Storkus WJ. Treatment-enhanced CD4+Foxp3+ glucocorticoid-induced TNF receptor family related high regulatory tumor-infiltrating T cells limit the effectiveness of cytokine-based immunotherapy. J Immunol 2007; 178:34008.
  • 17
    Navarro J, Aristimuno C, Sanchez-Ramon S et al. Circulating dendritic cells subsets and regulatory T-cells at multiple sclerosis relapse: differential short-term changes on corticosteroids therapy. J Neuroimmunol 2006; 176:15361.